Trial Profile

A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERAS-801 (Primary)
Indications Glioblastoma
Focus Adverse reactions
Acronyms THUNDERBBOLT-1
Sponsors Erasca; Katmai Pharmaceuticals

Most Recent Events

17 Aug 2025 Planned primary completion date changed from 30 Jun 2025 to 31 Aug 2025.
10 Feb 2025 Planned primary completion date changed from 31 Jan 2025 to 30 Jun 2025.
17 May 2024 According to an Erasca media release, due to the desire to focus internal resources on developing naporafenib and the RAS-targeting franchise, Erasca is exploring further advancement of ERAS-801 via select investigator-sponsored trial(s).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com